Oleksandr Veretelnyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oleksandr Veretelnyk has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiia Khilkovets
Zaporizhzhia State Medical and Pharmaceutical University
1 shared publication - Andrii Bilay1 shared publication
- H. I. Makurina
Zaporizhzhia State Medical and Pharmaceutical University
1 shared publication - I. M. Bilai
Zaporizhzhia State Medical and Pharmaceutical University
1 shared publication N.Yu. Onishchenko
1 shared publication- Nataliya Yuriivna Reznichenko
Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia
1 shared publication
Latest Publications
- Open Access
- 29 September 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Dermatology, Venerology, Cosmetology
- No. 3,p. 56-66
Clinical study of short-term and delayed efficacy of isotretinoin in treatment of patients with acne vulgaris and acne conglobata
Objective — to determine the long-term effectiveness of isotretinoin Lidose in comparison with classic isotretinoin. Materials and methods. The study included 194 patients (124 women and 70 men) aged 18—40 years with moderate and severe acne. Depending on the treatment method, the patients were divided into two groups. Group A (comparison) included 95 patients with acne vulgaris or conglobata who used isotretinoin; group B (experimental) included 99 patients who used Isotretinoin Lidose. The examination was performed before treatment, 3 and 6 months after its initiation. After 6 months, patients of both groups were divided into 4 subgroups each depending on the cumulative dose of received isotretinoin: A1 — received less than 120 mg/kg of regular isotretinoin; B1 — less than 120 mg/kg of isotretinoin Lidose; A2 — 120 mg/kg of regular isotretinoin; B2 — 120 mg/kg of isotretinoin Lidose; A3 — 150 mg/kg of regular isotretinoin; B3 — 150 mg/kg of isotretinoin Lidose; A4 — more than 150 mg/kg of regular isotretinoin due to additional administration of 10 mg/day after reaching the cumulative dose by the 12th month of treatment; B4 — more than 150 mg/kg of isotretinoin Lidose due to additional administration of 8 mg/day after reaching the cumulative dose by the 12th month of treatment. Patients of 8 subgroups were examined 12 months after treatment initiation. A score assessment of acne severity was performed using the IGA scale, and a questionnaire was administered to patients and doctors to assess the effectiveness of treatment 6 and 12 months after the start of therapy. The assessment of quality of life was carried out using the authorized Ukrainian translation of the DLQI. Results and discussion. Patients had less acne elements count and a lower IGA score in the group receiving isotretinoin Lidose at 3 and 6 months after the initiation of treatment compared to classic isotretinoin. In subgroups of patients receiving isotretinoin Lidose the number of post-acne scars was 14—30 % lower in 12 months after the initiation of therapy than in subgroups receiving classic isotretinoin. Relapses were more common in subgroups that did not receive the full cumulative dose of isotretinoin (less than 120 mg/kg). Analysis of the assessment of the effectiveness of therapy by patients and doctors in 12 months after its initiation showed similar results: a higher assessment score with isotretinoin Lidose compared to the corresponding cumulative doses with classic isotretinoin. Assessment of life quality in subgroups in 12 months after treatment initiation showed statistically better results in subgroups receiving isotretinoin Lidose compared to subgroups using classic isotretinoin. Conclusions. The use of isotretinoin Lidose provides a significantly better reduction in the number of acne elements and the IGA score compared to classic isotretinoin. The use of isotretinoin Lidose in the treatment of moderate and severe forms of acne reduces the post-acne scars and the disease relapse. The most effective cumulative dose of isotretinoin to prevent recurrence of acne vulgaris and acne conglobata is 150 mg/kg with a subsequent low maintenance dose of 8—10 mg/day.
- 29 September 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Dermatology, Venerology, Cosmetology
- No. 3,p. 56-66
Open AccessClinical study of short-term and delayed efficacy of isotretinoin in treatment of patients with acne vulgaris and acne conglobata
Objective — to determine the long-term effectiveness of isotretinoin Lidose in comparison with classic isotretinoin. Materials and methods. The study included 194 patients (124 women and 70 men) aged 18—40 years with moderate and severe acne. Depending on the treatment method, the patients were divided into two groups. Group A (comparison) included 95 patients with acne vulgaris or conglobata who used isotretinoin; group B (experimental) included 99 patients who used Isotretinoin Lidose. The examination was performed before treatment, 3 and 6 months after its initiation. After 6 months, patients of both groups were divided into 4 subgroups each depending on the cumulative dose of received isotretinoin: A1 — received less than 120 mg/kg of regular isotretinoin; B1 — less than 120 mg/kg of isotretinoin Lidose; A2 — 120 mg/kg of regular isotretinoin; B2 — 120 mg/kg of isotretinoin Lidose; A3 — 150 mg/kg of regular isotretinoin; B3 — 150 mg/kg of isotretinoin Lidose; A4 — more than 150 mg/kg of regular isotretinoin due to additional administration of 10 mg/day after reaching the cumulative dose by the 12th month of treatment; B4 — more than 150 mg/kg of isotretinoin Lidose due to additional administration of 8 mg/day after reaching the cumulative dose by the 12th month of treatment. Patients of 8 subgroups were examined 12 months after treatment initiation. A score assessment of acne severity was performed using the IGA scale, and a questionnaire was administered to patients and doctors to assess the effectiveness of treatment 6 and 12 months after the start of therapy. The assessment of quality of life was carried out using the authorized Ukrainian translation of the DLQI. Results and discussion. Patients had less acne elements count and a lower IGA score in the group receiving isotretinoin Lidose at 3 and 6 months after the initiation of treatment compared to classic isotretinoin. In subgroups of patients receiving isotretinoin Lidose the number of post-acne scars was 14—30 % lower in 12 months after the initiation of therapy than in subgroups receiving classic isotretinoin. Relapses were more common in subgroups that did not receive the full cumulative dose of isotretinoin (less than 120 mg/kg). Analysis of the assessment of the effectiveness of therapy by patients and doctors in 12 months after its initiation showed similar results: a higher assessment score with isotretinoin Lidose compared to the corresponding cumulative doses with classic isotretinoin. Assessment of life quality in subgroups in 12 months after treatment initiation showed statistically better results in subgroups receiving isotretinoin Lidose compared to subgroups using classic isotretinoin. Conclusions. The use of isotretinoin Lidose provides a significantly better reduction in the number of acne elements and the IGA score compared to classic isotretinoin. The use of isotretinoin Lidose in the treatment of moderate and severe forms of acne reduces the post-acne scars and the disease relapse. The most effective cumulative dose of isotretinoin to prevent recurrence of acne vulgaris and acne conglobata is 150 mg/kg with a subsequent low maintenance dose of 8—10 mg/day.
- Open Access
- 6 September 2022
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 24 (4) , 425-430
Immunohistochemical characteristics of inducible nitric oxide synthase and estrogen receptors alpha expression in patients with keratoderma climactericum
Aim. To examine the characteristics of immunohistochemical expression of inducible nitric oxide synthase and estrogen receptors alpha in patients with keratoderma climactericum compared to postmenopausal women with clinically intact skin, to reveal possible correlation between these markers’ expression levels and pathomorphogenesis of menopausal keratoderma. Materials and methods. The pathomorphological and immunohistochemical analysis was performed on the biopsy material of 22 patients with keratoderma climactericum, who constituted the study group, and on the autopsy material from 32 women in a postmenopausal period without any signs of climacteric keratoderma, who were considered as a control group. Results. A significant difference was found in the area and intensity of inducible nitric oxide synthase expression between the study group diagnosed with keratoderma climactericum and the control group with unaffected skin, with increasing expression parameters among patients with keratoderma. A significant difference was also observed in the area and intensity of estrogen receptors alpha expression between the study and the control group, this time with increasing expression parameters among the control group. Conclusions. Patients with keratoderma climactericum demonstrate statistically significantly higher levels of nuclear and cytoplasmatic expression of inducible nitric oxide synthase in epidermal and dermal cells than individuals from the control group, which may indicate acute inflammation as a part of climacteric keratoderma pathogenesis. The area and intensity of estrogen receptors alpha expression in material from patients diagnosed with menopausal keratoderma are lower than in the material from the control group, which demonstrates a correlation between estrogen-deficient state in postmenopausal period and the development of skin changes in women with keratoderma climactericum.
- 6 September 2022
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 24 (4) , 425-430
Open AccessImmunohistochemical characteristics of inducible nitric oxide synthase and estrogen receptors alpha expression in patients with keratoderma climactericum
Aim. To examine the characteristics of immunohistochemical expression of inducible nitric oxide synthase and estrogen receptors alpha in patients with keratoderma climactericum compared to postmenopausal women with clinically intact skin, to reveal possible correlation between these markers’ expression levels and pathomorphogenesis of menopausal keratoderma. Materials and methods. The pathomorphological and immunohistochemical analysis was performed on the biopsy material of 22 patients with keratoderma climactericum, who constituted the study group, and on the autopsy material from 32 women in a postmenopausal period without any signs of climacteric keratoderma, who were considered as a control group. Results. A significant difference was found in the area and intensity of inducible nitric oxide synthase expression between the study group diagnosed with keratoderma climactericum and the control group with unaffected skin, with increasing expression parameters among patients with keratoderma. A significant difference was also observed in the area and intensity of estrogen receptors alpha expression between the study and the control group, this time with increasing expression parameters among the control group. Conclusions. Patients with keratoderma climactericum demonstrate statistically significantly higher levels of nuclear and cytoplasmatic expression of inducible nitric oxide synthase in epidermal and dermal cells than individuals from the control group, which may indicate acute inflammation as a part of climacteric keratoderma pathogenesis. The area and intensity of estrogen receptors alpha expression in material from patients diagnosed with menopausal keratoderma are lower than in the material from the control group, which demonstrates a correlation between estrogen-deficient state in postmenopausal period and the development of skin changes in women with keratoderma climactericum.